Fosamax jawbone danger not disclosed in current ads
In this morning’s Washington Post, a letter to the editor criticized the advertisement of Fosamax on television given the risk of jawbone infections. Ronald S. Brown, a professor of oral diagnosis at the Howard University College of Dentistry, stated:
It is especially troubling to see television ads for bisphosphonates such as Boniva and Fosamax. Certainly, these medications appear to be useful in treating osteoporosis, but they also appear to have serious risks in an as-yet-unknown percentage of patients. Jawbone infections known as bisphosphonate-associated osteonecrosis (BON) have serious morbidity and mortality issues and are difficult to treat. It is scandalous to allow these drugs to be advertised on television.
Our Fosamax lawyers represent victims who suffered osteonecrosis of the jaw after taking the oral bisphosphonate for treatment of osteoporosis. While Fosamax is advertised to strengthen bones and prevent fractures, the drug actually inhibits bone turnover in the jaw, which can lead to the serious jawbone infection. Osteonecrosis of the Jaw (also known as ONJ or BON), involves jawbone decay which is irreversible, painful and potentially disfiguring.
Merck (the manufacturer) has failed to warn of the Fosomax jawbone danger and continues to promote the use of the medication without disclosing the extent of this risk. One of the main recommendations made by experts to prevent deterioration of the jawbone is to avoid any dental proceedures after taking Fosamax. Merck’s failure to warn of this side effect is leading to new injuries every day for women across the country.
>>INFORMATION: Fosamax Lawsuits
If you, a friend or family member have taken Fosamax and suffered a jawbone injury, request a free consultation and claim evaluation to find out if you have a claim.
